FDA’s Peter Marks overrode reviewers’ call to reject Sarepta’s new Duchenne gene therapy

Pe­ter Marks, the se­nior FDA of­fi­cial who over­sees the reg­u­la­tion of gene ther­a­pies, over­rode agency re­view­ers’ de­ci­sion to re­ject Sarep­ta Ther­a­peu­tics’ Duchenne mus­cu­lar dy­s­tro­phy gene ther­a­py af­ter he dis­agreed with parts of their in­ter­pre­ta­tion of the lim­it­ed ef­fi­ca­cy da­ta.

The FDA on Thurs­day grant­ed ac­cel­er­at­ed ap­proval to Sarep­ta’s gene ther­a­py, to be mar­ket­ed as Ele­v­idys, in boys aged 4 and 5 years old. The de­ci­sion fol­lowed months of reg­u­la­to­ry twists and a close vote by an ad­vi­so­ry com­mit­tee.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN